BankPlus Trust Department Makes New Investment in Intuitive Surgical, Inc. (NASDAQ:ISRG)

BankPlus Trust Department bought a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 53 shares of the medical equipment provider’s stock, valued at approximately $28,000.

A number of other hedge funds have also recently modified their holdings of the stock. Berbice Capital Management LLC acquired a new position in Intuitive Surgical in the fourth quarter valued at $26,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Intuitive Surgical in the 3rd quarter valued at about $33,000. Decker Retirement Planning Inc. acquired a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $36,000. Capital Performance Advisors LLP purchased a new position in Intuitive Surgical during the 3rd quarter worth approximately $38,000. Finally, Sierra Ocean LLC purchased a new position in Intuitive Surgical during the 4th quarter worth approximately $40,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Trading Down 2.9 %

ISRG stock opened at $573.74 on Wednesday. The company’s 50-day moving average price is $567.01 and its 200 day moving average price is $527.27. Intuitive Surgical, Inc. has a 52 week low of $364.17 and a 52 week high of $616.00. The company has a market cap of $204.35 billion, a P/E ratio of 89.51, a P/E/G ratio of 5.85 and a beta of 1.39.

Analyst Ratings Changes

Several research firms have recently weighed in on ISRG. Citigroup increased their price objective on Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a report on Friday, January 24th. UBS Group increased their price target on shares of Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Raymond James lifted their price objective on shares of Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a research note on Friday, January 24th. Erste Group Bank upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 19th. Finally, Truist Financial raised their price target on Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a report on Friday, January 24th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $613.10.

Insider Activity

In related news, EVP Robert Desantis sold 376 shares of Intuitive Surgical stock in a transaction on Friday, November 29th. The stock was sold at an average price of $539.00, for a total transaction of $202,664.00. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,967,734. The trade was a 6.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Myriam Curet sold 408 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $589.75, for a total value of $240,618.00. Following the completion of the sale, the executive vice president now directly owns 353 shares in the company, valued at $208,181.75. This trade represents a 53.61 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 6,240 shares of company stock worth $3,529,040. Company insiders own 0.80% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.